Fresh analysis indicates that individuals who stop using new weight-loss injections like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who end conventional lifestyle plans.
Findings released in a leading medical journal points out that while obese individuals frequently drop substantial amounts of their total mass while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"Users buying such drugs must be informed of the danger of quick rebound weight gain when the therapy ends," warns expert Dr. Susan Jebb.
This pace of recovery means a reversion to starting mass in about 18 months.
Comparing Approaches
The study, which examined 37 of trials involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with older methods.
Researchers point out that people who lose weight through lifestyle changes alone typically see a less rapid creep back—around 100 grams monthly—once they finish.
Explaining the Fast Rebound
Experts propose the mode of action of the injections explains the accelerated regain.
These medications mimic a natural hormone called GLP-1, which controls hunger.
"Artificially providing GLP-1 concentrations far above than normal could lead to the body to produce less of its own natural hormone, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this hormone supplement results in hunger is uncontrolled, making binge eating much more probable."
An Ongoing Condition?
Health authorities advise the injections for people with obesity-related health risks, alongside recommended diet and exercise modifications.
A number of clinicians argue that, due to the high risk of weight regain, the therapy might need to be life-long.
This view is echoed by drug manufacturers, who note that the findings "underscore the long-term character of excess weight," similar to managing conditions like hypertension.
Patient Testimonies
Individuals who have come off the jabs report a powerful return of appetite.
"I experienced a trigger activating and you become ravenous," recalled an individual.
This difficulty is compounded if users have not developed lasting dietary or behavioural modifications during therapy.
Significant Use
Recent estimates show that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with desire being substantial.
- Use is more common among females compared to men.
- The middle-aged age group shows the greatest usage rates.
- Many obtain the medications through private healthcare rather than public health services.
In conclusion, experts stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent solution and maintained weight loss hinges on ongoing lifestyle changes.
